Stanford Medicine Develops Universal Nasal Vaccine

Scientists at Stanford Medicine, led by Bala Pulendran, have developed a novel nasal spray vaccine that has shown broad protection against a range of respiratory threats in mice. Unlike traditional vaccines, this 'universal vaccine' stimulates the innate immune system by mimicking communication signals between immune cells, rather than targeting specific pathogens. The study, published in Science (journal), demonstrated protection against viruses like COVID-19, Influenza, and Respiratory syncytial virus, as well as bacteria such as Staphylococcus aureus and Acinetobacter baumannii, and even House dust mite allergens. If successful in human trials, which are planned, this vaccine could replace multiple annual jabs for respiratory illnesses and offer rapid protection against emerging pandemics. Experts like Ian Jones (virologist) and Jonathan Ball (virologist) acknowledge the potential but also raise important safety considerations regarding a hyper-ready immune system. Bala Pulendran estimates the vaccine could be available within five to seven years, pending funding and successful trials.